Works matching DE "VISMODEGIB"
Results: 54
Vismodegib: The first drug approved for advanced and metastatic basal cell carcinoma.
- Published in:
- Journal of Postgraduate Medicine, 2013, v. 59, n. 1, p. 48, doi. 10.4103/0022-3859.109494
- By:
- Publication type:
- Article
Synthesis of Vismodegib Derivatives as Potential Smo Agonist: A Case of Undergraduate Experimental Teaching.
- Published in:
- Russian Journal of General Chemistry, 2023, v. 93, n. 10, p. 2694, doi. 10.1134/S1070363223100249
- By:
- Publication type:
- Article
Crystal structure of vismodegib, C<sub>19</sub>H<sub>14</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>3</sub>S.
- Published in:
- Powder Diffraction, 2023, v. 38, n. 1, p. 1, doi. 10.1017/S0885715622000446
- By:
- Publication type:
- Article
Effectiveness, Safety and Utilization of Vismodegib for Locally Advanced Basal Cell Carcinoma Under Real-world Conditions: Noninterventional Cohort Study JONAS.
- Published in:
- Acta Dermato-Venereologica, 2022, v. 102, p. 1, doi. 10.2340/actadv.v102.293
- By:
- Publication type:
- Article
9q22.3 Microdeletion Syndrome with Multiple Basal Cell Carcinomas Treated with Vismodegib: Three Key Messages in One Patient.
- Published in:
- 2018
- By:
- Publication type:
- Case Study
Epidermal Cyst Formation and Hyperkeratosis in a Patient Treated with Vismodegib for Locally Advanced Basal Cell Carcinoma.
- Published in:
- 2015
- By:
- Publication type:
- Case Study
Combinations of PRI-724 Wnt/β-Catenin Pathway Inhibitor with Vismodegib, Erlotinib, or HS-173 Synergistically Inhibit Head and Neck Squamous Cancer Cells.
- Published in:
- International Journal of Molecular Sciences, 2023, v. 24, n. 13, p. 10448, doi. 10.3390/ijms241310448
- By:
- Publication type:
- Article
Radiation Sensitization of Basal Cell and Head and Neck Squamous Cell Carcinoma by the Hedgehog Pathway Inhibitor Vismodegib.
- Published in:
- International Journal of Molecular Sciences, 2018, v. 19, n. 9, p. 2485, doi. 10.3390/ijms19092485
- By:
- Publication type:
- Article
Hedgehog inhibitors with and without adjunctive therapy in treatment of locally advanced basal cell carcinoma.
- Published in:
- International Journal of Dermatology, 2022, v. 61, n. 1, p. 118, doi. 10.1111/ijd.15836
- By:
- Publication type:
- Article
Efficacy and safety profile of vismodegib in a real‐world setting cohort of patients with advanced basal cell carcinoma in Argentina.
- Published in:
- International Journal of Dermatology, 2020, v. 59, n. 5, p. 627, doi. 10.1111/ijd.14780
- By:
- Publication type:
- Article
Cholestatic hepatic injury associated with vismodegib, aspirin, and naproxen use: a case study and review of vismodegib safety.
- Published in:
- International Journal of Dermatology, 2015, v. 54, n. 3, p. 370, doi. 10.1111/ijd.12543
- By:
- Publication type:
- Article
Giant morphea-form basal cell carcinoma of the umbilicus: Successful debulking with vismodegib.
- Published in:
- Rare Tumors, 2018, v. 10, n. 1, p. 1, doi. 10.1177/2036361318772938
- By:
- Publication type:
- Article
Raman Spectroscopy to Monitor the Delivery of a Nano-Formulation of Vismodegib in the Skin.
- Published in:
- Applied Sciences (2076-3417), 2023, v. 13, n. 13, p. 7687, doi. 10.3390/app13137687
- By:
- Publication type:
- Article
Vismodegib: In Locally Advanced or Metastatic Basal Cell Carcinoma.
- Published in:
- 2012
- By:
- Publication type:
- Journal Article
An alternative method for the preparation of vismodegib: A tool for an undergraduate laboratory course.
- Published in:
- Journal of Chemical Research, 2023, v. 47, n. 6, p. 1, doi. 10.1177/17475198231214490
- By:
- Publication type:
- Article
Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug-drug interaction potential.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2013, v. 71, n. 1, p. 193, doi. 10.1007/s00280-012-1996-6
- By:
- Publication type:
- Article
The Use of Noninvasive Optical Coherence Tomography to Monitor the Treatment Progress of Vismodegib and Imiquimod 5% Cream in a Transplant Patient with Advanced Basal Cell Carcinoma of the Nose.
- Published in:
- 2016
- By:
- Publication type:
- Case Study
Safety and efficacy of vismodegib in relapsed/refractory acute myeloid leukaemia: results of a phase Ib trial.
- Published in:
- British Journal of Haematology, 2019, v. 185, n. 3, p. 595, doi. 10.1111/bjh.15571
- By:
- Publication type:
- Article
Rational Design of Polymeric Hybrid Micelles with Highly Tunable Properties to Co-Deliver MicroRNA-34a and Vismodegib for Melanoma Therapy.
- Published in:
- Advanced Functional Materials, 2015, v. 25, n. 48, p. 7457, doi. 10.1002/adfm.201503115
- By:
- Publication type:
- Article
About face: can Vismodegib change the treatment paradigm of locally advanced basal cell carcinoma?
- Published in:
- ANZ Journal of Surgery, 2021, v. 91, n. 6, p. 1304, doi. 10.1111/ans.16399
- By:
- Publication type:
- Article
Combination Trimodality Therapy Using Vismodegib for Basal Cell Carcinoma of the Face.
- Published in:
- Case Reports in Oncological Medicine, 2015, v. 2015, p. 1, doi. 10.1155/2015/827608
- By:
- Publication type:
- Article
Hepatotoxicity with Vismodegib: An MD Anderson Cancer Center and Research on Adverse Drug Events and Reports Project.
- Published in:
- Drugs in R&D, 2017, v. 17, n. 1, p. 211, doi. 10.1007/s40268-016-0168-2
- By:
- Publication type:
- Article
Vismodegib for Basal Cell Carcinoma and Beyond: What Dermatologists Need to Know.
- Published in:
- 2022
- By:
- Publication type:
- Case Study
Vismodegib, an antagonist of hedgehog signaling, directly alters taste molecular signaling in taste buds.
- Published in:
- Cancer Medicine, 2015, v. 4, n. 2, p. 245, doi. 10.1002/cam4.350
- By:
- Publication type:
- Article
Radial shock waves prevent growth retardation caused by the clinically used drug vismodegib in ex vivo cultured bones.
- Published in:
- Scientific Reports, 2020, v. 10, n. 1, p. 1, doi. 10.1038/s41598-020-69904-0
- By:
- Publication type:
- Article
Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Response to 'British Association of Dermatologists guidelines for the management of adults with basal cell carcinoma 2021': vismodegib and indications for its use.
- Published in:
- British Journal of Dermatology, 2022, v. 187, n. 5, p. 832, doi. 10.1111/bjd.21788
- By:
- Publication type:
- Article
Case report: Complete response of recurrent locally advanced basal cell carcinoma following addition of vismodegib to neoadjuvant cemiplimab therapy.
- Published in:
- 2025
- By:
- Publication type:
- Case Study
Prolonged treatment response of a giant basal cell carcinoma to vismodegib after treatment cessation.
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2023, v. 37, n. 7, p. e933, doi. 10.1111/jdv.19032
- By:
- Publication type:
- Article
Analysis of efficacy and safety of vismodegib therapy in patients with advanced basal cell carcinoma – real world multicenter cohort study.
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2022, v. 36, n. 8, p. 1219, doi. 10.1111/jdv.18070
- By:
- Publication type:
- Article
Vismodegib for periocular and orbital basal cell carcinoma.
- Published in:
- Current Medical Literature: Ophthalmology, 2014, v. 24, n. 1, p. 9
- By:
- Publication type:
- Article
Clinical Characteristics of an Italian Patient Population with Advanced BCC and Real-Life Evaluation of Hedgehog Pathway Inhibitor Safety and Effectiveness.
- Published in:
- Dermatology (10188665), 2023, v. 239, n. 6, p. 868, doi. 10.1159/000531280
- By:
- Publication type:
- Article
Real-World Experience with Vismodegib on Advanced and Multiple BCCs: Data from the RELIVIS Study.
- Published in:
- Dermatology (10188665), 2023, v. 239, n. 5, p. 685, doi. 10.1159/000530813
- By:
- Publication type:
- Article
Vismodegib in Locally Advanced Basal Cell Carcinoma in Slovenia.
- Published in:
- Dermatology (10188665), 2023, v. 239, n. 1, p. 158, doi. 10.1159/000525612
- By:
- Publication type:
- Article
Orbito-scleral-sinus invasion of basal cell carcinoma in an immunocompromised patient on vismodegib.
- Published in:
- Orbit, 2021, v. 40, n. 2, p. 155, doi. 10.1080/01676830.2020.1753783
- By:
- Publication type:
- Article
Upfront Radiotherapy with Concurrent and Adjuvant Vismodegib Is Effective and Well-Tolerated in a Patient with Advanced, Multifocal Basal Cell Carcinoma.
- Published in:
- 2018
- By:
- Publication type:
- Case Study
Vismodegib: A smoothened inhibitor for the treatment of advanced basal cell carcinoma.
- Published in:
- Indian Dermatology Online Journal, 2013, v. 4, n. 4, p. 365, doi. 10.4103/2229-5178.120685
- By:
- Publication type:
- Article
The effectiveness of vismodegib in patients with advanced periocular basal cell carcinoma: a case series of 13 patients.
- Published in:
- 2022
- By:
- Publication type:
- Case Study
Vismodegib (ERIVEDGE) pregnancy prevention programme: assessment of risk awareness.
- Published in:
- Journal of Dermatological Treatment, 2022, v. 33, n. 1, p. 466, doi. 10.1080/09546634.2020.1770166
- By:
- Publication type:
- Article
The dawn of hedgehog inhibitors: Vismodegib.
- Published in:
- Journal of Pharmacology & Pharmacotherapeutics, 2013, v. 4, n. 1, p. 4, doi. 10.4103/0976-500X.107628
- By:
- Publication type:
- Article
The Topical Nanodelivery of Vismodegib Enhances Its Skin Penetration and Performance In Vitro While Reducing Its Toxicity In Vivo.
- Published in:
- Pharmaceutics, 2021, v. 13, n. 2, p. 186, doi. 10.3390/pharmaceutics13020186
- By:
- Publication type:
- Article
Enhancing the Bioavailability and Efficacy of Vismodegib for the Control of Skin Cancer: In Vitro and In Vivo Studies.
- Published in:
- Pharmaceuticals (14248247), 2022, v. 15, n. 2, p. 126, doi. 10.3390/ph15020126
- By:
- Publication type:
- Article
Analysis of Longitudinal‐Ordered Categorical Data for Muscle Spasm Adverse Event of Vismodegib: Comparison Between Different Pharmacometric Models.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2020, v. 9, n. 2, p. 96, doi. 10.1002/psp4.12487
- By:
- Publication type:
- Article
Two different scenarios of advanced basal cell carcinomas during the use of vismodegib: Cases of oral administration and administration directly to the stomach.
- Published in:
- Drug Discoveries & Therapeutics, 2019, v. 13, n. 2, p. 122, doi. 10.5582/ddt.2019.01020
- By:
- Publication type:
- Article
Sustained Suppression of Gorlin Syndrome-Associated Basal Cell Carcinomas with Vismodegib or Sonidegib: A Case Series.
- Published in:
- Current Oncology, 2023, v. 30, n. 10, p. 9156, doi. 10.3390/curroncol30100661
- By:
- Publication type:
- Article
Eight years of experience with vismodegib for advanced and multiple basal cell carcinoma patients in the Netherlands: a retrospective cohort study.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Long‐term efficacy of a Vismodegib regime including a 1‐week drug holiday every month in two patients with Gorlin Goltz syndrome.
- Published in:
- Dermatologic Therapy, 2022, v. 35, n. 3, p. 1, doi. 10.1111/dth.15293
- By:
- Publication type:
- Article
Vismodegib treatment in advanced basal cell carcinomas: Real‐life experience.
- Published in:
- Dermatologic Therapy, 2022, v. 35, n. 1, p. 1, doi. 10.1111/dth.15195
- By:
- Publication type:
- Article
Efficacy and tolerability of vismodegib treatment in locally advanced and metastatic basal cell carcinoma: Retrospective real‐life data.
- Published in:
- Dermatologic Therapy, 2021, v. 34, n. 6, p. 1, doi. 10.1111/dth.15122
- By:
- Publication type:
- Article
Sonidegib after vismodegib discontinuation in a patient with Gorlin–Goltz syndrome and multiple basal cell carcinomas.
- Published in:
- Dermatologic Therapy, 2021, v. 34, n. 5, p. 1, doi. 10.1111/dth.15095
- By:
- Publication type:
- Article